Get started
Author

Sebastien J. Hazard

Observed names: S Hazard, S. Hazard, S.J. Hazard, Sebastien Hazard, Sébastien Hazard
ORCID: 0000-0001-5740-1188
Observed ORCID: 0000-0001-5740-1188
OpenAlex ID: A5089764941
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
2019 · Josep M. del Campo, Ursula A. Matulonis, et al. · Journal of Clinical Oncology · 191
Safety and dose modification for patients receiving niraparib
2018 · J.S. Berek, U.A. Matulonis, et al. · Annals of Oncology · 189
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study
2014 · Thomas J. Lynch, David R. Spigel, et al. · Journal of Thoracic Oncology · 56
Increased risk of brain metastases in ovarian cancer patients with BRCA mutations
2019 · Elena Ratner, Mohan Bala, et al. · Gynecologic Oncology · 53
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer
2015 · Corey J. Langer, Mark A. Socinski, et al. · American Journal of Clinical Oncology · 51
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
2019 · Michel Fabbro, Kathleen N. Moore, et al. · Gynecologic Oncology · 48
PDF
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
2022 · Laura M. Spring, Hyo Han, et al. · Nature Cancer · 33
PDF
Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study
2015 · A.J. Wozniak, M.P. Kosty, et al. · Clinical Oncology · 28
ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC).
2019 · Anne-Claire Hardy-Bessard, Kathleen N. Moore, et al. · Journal of Clinical Oncology · 22
BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
2023 · Capucine Baldini, Vincent Goldschmidt, et al. · Journal of Clinical Oncology · 21
First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices
2016 · Orsolya E. Lunacsek, Arliene Ravelo, et al. · Drugs - Real World Outcomes · 16
PDF
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
2017 · Ursula A. Matulonis, Jorn Herrstedt, et al. · Journal of Clinical Oncology · 14
A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study
2018 · A. Gonzalez, M.R. Mirza, et al. · Annals of Oncology · 12
Correction to: “Safety and dose modification for patients receiving niraparib”
2018 · J.S. Berek, U.A. Matulonis, et al. · Annals of Oncology · 12
PDF
The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial
2017 · J. Wang, Z-Y. Zhang, et al. · Annals of Oncology · 11
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
2017 · Mansoor Raza Mirza, Bradley J. Monk, et al. · Journal of Clinical Oncology · 10
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab–carboplatin–paclitaxel and carboplatin–paclitaxel: A retrospective cohort study
2014 · Corey Langer, Arliene Ravelo, et al. · Lung Cancer · 9
Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC)
2017 · M. Fabbro, K.N. Moore, et al. · Annals of Oncology · 8
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
2017 · Jose Maria Del Campo, Mansoor Raza Mirza, et al. · Journal of Clinical Oncology · 8
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer
2026 · Gael Roth, Pascal Artru, et al. · Nature · 7
Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer
2019 · U.A. Matulonis, B.J. Monk, et al. · Gynecologic Oncology · 7
Tissue distribution and brain penetration of niraparib in tumor bearing mouse models and its clinical relevance.
2021 · Keyur Gada, Geeta Sharma, et al. · Journal of Clinical Oncology · 6
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study
2015 · Michael P. Kosty, Antoinette J. Wozniak, et al. · Targeted Oncology · 6
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
2019 · Mansoor Raza Mirza, Bin Feng, et al. · Journal of Clinical Oncology · 5
Effectiveness of bevacizumab exposure beyond disease progression in patients with non–small‐cell lung cancer: analyses of the ARIES observational cohort study
2016 · Larry Leon, Michael Kosty, et al. · Pharmacoepidemiology and Drug Safety · 5
Works count: 45
Citation count: 847
H-index: 12
I10-index: 16
Year
Topic
Type